IP Library Granted Patent US 11,155,887
Granted Patent B2
US 11,155,887 · App. 17/221,451 · Granted Oct 26, 2021

Rapid diagnostic test using colorimetric LAMP

Inventors: Nathan Tanner (West Newbury, MA); Yinhua Zhang (North Reading, MA); Gregory Patton (Peabody, MA); Guoping Ren (Danvers, MA); Zhiru Li (Lexington, MA); Nicole Nichols (Reading, MA)
Assignee: New England Biolabs, Inc.
C12Q1/701G01N21/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,155,887
App. No.
17/221,451
Granted
Oct 26, 2021
Kind
B2
Abstract

Kits and methods are provided for performing multiplex Loop-Mediated Isothermal Amplification (LAMP) reactions. These kits and methods are directed to specific and sensitive methods of target nucleic acid detection and more specifically pathogen diagnostics such as detection of Coronavirus. The kits and methods utilize a plurality of sets of oligonucleotide primers for targeting the viral nucleic acid target.

Claims (27)

1. A method for determining whether a target nucleic acid is present in a saliva sample from a subject, comprising:

(a) obtaining the saliva sample in a saliva collection container;

(b) incubating the saliva sample with a reducing agent at a temperature in the range of 65° C.-95° C.;

(c) directly combining an aliquot of the product of step (b) with a reaction mix in a reaction container containing one or more sets of oligonucleotide primers for amplifying a target nucleic acid by Loop-Mediated Isothermal Amplification (LAMP), and a mastermix comprising a strand-displacing DNA polymerase and nucleoside triphosphates;

(d) incubating the reaction mix under conditions suitable for LAMP; and

(e) detecting an amplification product in the reaction mix, corresponding to the presence of the target nucleic acid in the saliva sample.

2. The method according to claim 1 , wherein the reaction mix of (c) further comprises an indicator and step (e) comprises detecting the target nucleic acid in the saliva sample by a change in the indicator.

3. The method according to claim 1 , further comprising: detecting the change in the indicator through the walls of the reaction container.

4. The method according to claim 2 , wherein the indicator is selected from the group consisting of a metallochromic dye, a pH sensitive color dye, an intercalating dye and a fluorescent reporter indicator.

5. The method according to claim 1 , wherein the incubation of (b) is for one hour or less.

6. The method according to claim 1 , wherein (b) comprises incubating the saliva sample with the reducing agent and a detergent.

7. The method according to claim 1 , wherein the reaction mix of (c) further comprises a guanidinium salt.

8. The method according to claim 1 , wherein (b) comprises incubating the saliva sample with the reducing agent and an RNase inhibitor.

9. The method according to claim 1 , wherein (b) comprises incubating the saliva sample with the reducing agent and a proteinase.

10. The method according to claim 1 , wherein the target nucleic acid is a viral RNA and the mastermix further comprises a reverse transcriptase and ribonucleoside triphosphates.

11. The method according to claim 10 , wherein the viral RNA is a Coronavirus RNA.

12. The method according to claim 2 , wherein a change in the indicator indicates that the aliquot of the sample used in step (c) comprises at least 20 copies of the target nucleic acid.

13. The method according to claim 1 , wherein the reaction mix of (c) comprises two or more sets of oligonucleotide primers that hybridize to a single target nucleic acid.

14. The method according to claim 1 , wherein the saliva collection container is a tube that holds a volume of at least 900 μl.

15. A kit, comprising:

(a) a saliva collection container comprising a reducing agent in a buffer;

(b) a mastermix comprising a strand displacing polymerase, a reverse transcriptase, reversible inhibitors of the strand displacing polymerase and the reverse transcriptase and ribonucleoside triphosphates, wherein the mastermix is in a second container that has walls that are transparent to visible light and/or fluorescence; and

(c) an indicator selected from a metallochromic dye, a pH sensitive color dye, an intercalating dye and a fluorescent reporter, wherein the indicator is the second container or in a third container.

16. The kit according to claim 15 , further comprising (d) one or more sets of oligonucleotide primers for hybridizing to the target nucleic acid.

17. The kit according to claim 15 , further comprising uracil DNA glycosylase.

18. The kit according to claim 15 , wherein the master mix and/or the indicator is lyophilized.

19. The kit according to claim 15 , wherein the saliva collection container is a tube capable of holding a volume of 900 μl.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2021
From: TANNER, NATHAN; ZHANG, YINHUA; REN, GUOPING; PATTON, GREGORY; LI, ZHIRU; NICHOLS, NICOLE
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 056910/0355 →
Continuity (9)
Continuation 17122979 · Dec 15, 2020
Continuation 16938575 · Jul 24, 2020
Provisional Application 63048556 · Jul 6, 2020
Provisional Application 63027216 · May 19, 2020
Provisional Application 63022303 · May 8, 2020
Provisional Application 63013442 · Apr 21, 2020
Provisional Application 63001909 · Mar 30, 2020
Provisional Application 62988696 · Mar 12, 2020
Related Publication 20210285065A1 · Sep 16, 2021